Members of our team had the opportunity to present a new poster abstract at NASP inSPIRE 2026, which was held from September 22-25, 2026.
Authors
Sandra Poon, PharmD, AAHIVP; Dan Ge, PharmD; Andrew Wash, PharmD, PhD; Casey Fitzpatrick, PharmD; Ana Lopez Medina, PharmD, PhD; Jessica Mourani, PharmD
Background
-
The long-acting injectable lenacapavir (Yeztugo®), approved on July 19, 2025, introduces a biannual option for HIV pre-exposure prophylaxis (PrEP) that may help overcome adherence barriers associated with daily oral regimens.1
-
By requiring only twice-yearly injections, lenacapavir has the potential to substantially reduce the cognitive, behavioral, and logistical demands placed on patients using other forms of PrEP, thereby addressing well-documented gaps in real-world adherence and persistence.2
-
This treatment presents an opportunity for health-system specialty pharmacies (HSSPs) to proactively educated and engage patients on PrEP options.
Objectives
To describe the implementation of an HSSP pharmacist-driven workflow designed to identify, educate, and facilitate transition of appropriate oral PrEP patients to long-acting injectable PrEP.
-
1
Major new policy updates announced at the IAS 2025 conference: WHO recommends injectable lenacapavir for HIV prevention. World Health Organization. July 14, 2025. Accessed March 23, 2026. https;??www.who.int/news/item/14-07-2025-who-recommends-injectable-lenacapavir-for-hiv-prevention
-
2
Yeztugo® (Lenacapavir) is now the first and only FDA-approved HIV prevention option offering 6 months of protection. Gilead Sciences, Inc. June 18, 2025. Accessed March 23, 2025. https://www.gilead.com/news-details/2025/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-offering-6-months-of-protection
